IGC Pharma announced that the United States Patent and Trademark Office granted U.S. Patent No. 12,465,589, titled "Methods and Composition for Treating CNS Disorders," covering its lead Alzheimer’s candidate IGC‑AD1, a cannabinoid‑based therapy designed to address agitation and sleep disturbances in patients with Alzheimer’s disease.
The grant gives IGC Pharma exclusive rights to the composition and method, potentially extending market exclusivity beyond the standard five‑year period for drug patents. It strengthens the company’s intellectual‑property portfolio, supporting future regulatory submissions and positioning the company for licensing or partnership opportunities.
IGC‑AD1 is currently in Phase 2 CALMA trials for agitation and is being explored as a disease‑modifying therapy that targets amyloid plaques and tau tangles. The dual‑action approach—treating both behavioral symptoms and core disease mechanisms—sets the candidate apart from other treatments and underpins the strategic value of the patent.
CEO Ram Mukunda said the patent "further strengthens the robustness of our intellectual property portfolio as we move closer to commercialization of IGC‑AD1. It reinforces our position in developing differentiated therapies that target both the behavioral and disease‑modifying aspects of Alzheimer’s disease, with the goal of delivering safer, more effective solutions for patients and caregivers." The comment highlights the company’s confidence in the commercial trajectory of the candidate.
IGC Pharma’s portfolio also includes other patents, such as a low‑dose THC patent granted in September 2022, and the company leverages artificial intelligence to accelerate discovery and clinical development. The new patent adds a critical asset that could enhance the company’s competitive positioning in the growing Alzheimer’s market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.